{"entity":{"id":"paper-roa-her2-overexpression-gallbladder-gcr-2014","kind":"paper","name":"Overexpression of the HER2/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","aka":[],"tldr":"In 187 Chilean gallbladder cancers stained with breast cancer rules, about one in eight overexpressed HER2, one in five was borderline, and the HER2-positive patients did slightly worse, an early argument for HER2 drugs in this disease.","summary":"187 patients with gallbladder cancer (165 women, 22 men) with at least five years of follow-up and 75 controls were studied with an automated immunohistochemical technique using an anti-ErbB2 antibody, scored by the CAP/ASCO criteria for breast cancer.\n\nOverexpression of HER2/neu was observed in 12.8% of cases (0% mucosal, 14.3% muscular, 12.8% subserosal and 10.6% serosal tumours) and equivocal staining in 20%. Overexpression was more frequent in advanced and in better-differentiated tumours (13.8% and 17.4%), not significantly. Patients with overexpression had worse five-year survival than those without (34% versus 41%). The authors concluded that overexpression occurred in 14% of advanced cases and that this subgroup might benefit from HER2 pathway inhibitors.","asOf":"2026-09-24","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/24799970/"}],"tags":[],"related":[],"cancers":["gallbladder"],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["ihc","her2-testing-in-biliary-cancer"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Gastrointestinal Cancer Research","year":2014,"pmid":"24799970","authors":"Roa I, de Toro G, Schalper K, et al.","paperType":"observational","findings":["HER2 overexpression in 12.8% of 187 Chilean gallbladder cancers; equivocal staining in 20%.","Overexpression absent in mucosal tumours, 14.3% in muscular, 12.8% in subserosal, 10.6% in serosal.","Five-year survival 34% with overexpression versus 41% without."],"whatItMeans":"The largest Chilean HER2 series and the reason HER2 rates in the highest-incidence country are quoted at around 13%; scoring by breast rather than gastric rules explains part of the gap to the Japanese 31%.","caveats":["Immunohistochemistry only, no in situ hybridisation, so the 20% equivocal group is unresolved.","No DOI; PubMed record only."],"changedPractice":false,"participants":187},"route":"/key-papers/paper-roa-her2-overexpression-gallbladder-gcr-2014/","neighbours":{"cancer":[{"id":"gallbladder","kind":"cancer","name":"Gallbladder cancer","route":"/cancers/gallbladder/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"term":[{"id":"her2-testing-in-biliary-cancer","kind":"term","name":"HER2 testing in biliary tract cancer (IHC, ISH and NGS)","route":"/terms/her2-testing-in-biliary-cancer/"},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"}]}}